Literature DB >> 27802072

Prevalence of Prescription Opioid Misuse/Abuse as Determined by International Classification of Diseases Codes: A Systematic Review.

Carl L Roland, Joanita Lake, Gary M Oderda.   

Abstract

We conducted a systematic review to evaluate worldwide human English published literature from 2009 to 2014 on prevalence of opioid misuse/abuse in retrospective databases where International Classification of Diseases (ICD) codes were used. Inclusion criteria for the studies were use of a retrospective database, measured abuse, dependence, and/or poisoning using ICD codes, stated prevalence or it could be derived, and documented time frame. A meta-analysis was not performed. A qualitative narrative synthesis was used, and 16 studies were included for data abstraction. ICD code use varies; 10 studies used ICD codes that encompassed all three terms: abuse, dependence, or poisoning. Eight studies limited determination of misuse/abuse to an opioid user population. Abuse prevalence among opioid users in commercial databases using all three terms of ICD codes varied depending on the opioid; 21 per 1000 persons (reformulated extended-release oxymorphone; 2011-2012) to 113 per 1000 persons (immediate-release opioids; 2010-2011). Abuse prevalence in general populations using all three ICD code terms ranged from 1.15 per 1000 persons (commercial; 6 months 2010) to 8.7 per 1000 persons (Medicaid; 2002-2003). Prevalence increased over time. When similar ICD codes are used, the highest prevalence is in US government-insured populations. Limiting population to continuous opioid users increases prevalence. Prevalence varies depending on ICD codes used, population, time frame, and years studied. Researchers using ICD codes to determine opioid abuse prevalence need to be aware of cautions and limitations.

Entities:  

Keywords:  abuse; dependence; opioid; poisoning; prevalence; systematic review

Mesh:

Substances:

Year:  2016        PMID: 27802072     DOI: 10.1080/15360288.2016.1231739

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  6 in total

Review 1.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

2.  Drug use generations and patterns of injection drug use: Birth cohort differences among people who inject drugs in Los Angeles and San Francisco, California.

Authors:  Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Philippe Bourgois; Alex H Kral
Journal:  Drug Alcohol Depend       Date:  2017-04-19       Impact factor: 4.492

3.  Opioid-related emergency department visits and hospitalizations among patients with chronic gastrointestinal symptoms and disorders dually enrolled in the Department of Veterans Affairs and Medicare Part D.

Authors:  Salva N Balbale; Lishan Cao; Itishree Trivedi; Jonah J Stulberg; Katie J Suda; Walid F Gellad; Charlesnika T Evans; Neil Jordan; Laurie A Keefer; Bruce L Lambert
Journal:  Am J Health Syst Pharm       Date:  2022-01-05       Impact factor: 2.980

4.  An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose.

Authors:  Daniel C Beachler; Kelsey Hall; Renu Garg; Geetanjoli Banerjee; Ling Li; Luke Boulanger; Huseyin Yuce; Alexander M Walker
Journal:  Clin J Pain       Date:  2022-06-01       Impact factor: 3.423

5.  Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse.

Authors:  Pooja Lagisetty; Claire Garpestad; Angela Larkin; Colin Macleod; Derek Antoku; Stephanie Slat; Jennifer Thomas; Victoria Powell; Amy S B Bohnert; Lewei A Lin
Journal:  Drug Alcohol Depend       Date:  2021-02-13       Impact factor: 4.492

6.  Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data.

Authors:  Alexander M Walker; Lisa B Weatherby; M Soledad Cepeda; Daniel C Bradford
Journal:  Subst Abuse Rehabil       Date:  2019-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.